Early data show cancer progression associated with increased risk of death in patients with COVID-19

Research suggests treatment with combination of hydroxychloroquine and azithromycin also strongly associated with greater risk of death

Like Comment

In patients with cancer and COVID-19, cancer that is progressing was independently associated with an increased risk of death, according to an analysis of 928 patients.

COVID-19 treatment with both hydroxychloroquine and azithromycin was also strongly associated with increased risk of death, according to data from the COVID-19 and Cancer Consortium (CCC19) registry. The registry contains data from patients who have tested positive for COVID-19 and around 40% of patients in the registry also have active cancer.

The data was presented as part of the virtual scientific programme of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. 

Study at a Glance

Focus 30-day all-cause mortality 
Population 525 patients with cancer diagnosed with COVID-19 
Findings Cancer progression and treatment with hydroxychloroquine and azithromycin were associated with a 5.2-fold and 2.89-fold greater risk of death at 30 days compared with patients in remission/no evidence of disease 
Significance The findings could lead to better understanding of the relationship between cancer and COVID-19 to improve care for these patients 

To view full article and watch the video summary,
register to OnMedica and then click
'View full content'.

 

OnMedica

Editorial team, Wilmington Healthcare

OnMedica provides high-quality, easy to digest content and CPD for UK-based GPs and clinicians. Our team of expert editors and clinicians develops content across a wide range of topics in a variety of formats—expert articles, bitesize news and quizzes, courses, videos, and more. You can explore OnMedica via the homepage, drop down menu or by typing your topic of choice in the search bar. Why not find out how OnMedica can help you to keep up to date quickly and easily?
3638 Contributions
185 Followers
1 Following